von Tobias Borgers | Sep 14, 2021 | Abbvie
Copenhagen, Denmark; North Chicago, Ill. – Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical...
von Tobias Borgers | Sep 11, 2021 | Bayer
Onkologie bei Bayer Mit dem Ziel, das Leben von Menschen zu verbessern, arbeitet Bayer an der Erweiterung seines Portfolios für innovative Behandlungen. Der Forschungsansatz des Unternehmens priorisiert Ansätze, die das Potenzial haben, das Leben von Menschen...
von Tobias Borgers | Sep 6, 2021 | Bayer
Bayer Middle East has introduced its Alleye Home Monitoring Sponsorship Programme to the Egyptian healthcare sector, it has been confirmed. The global pharma giant is reportedly working with some of the country’s top-rated eye hospitals to “support Egypt’s...
von Tobias Borgers | Aug 29, 2021 | Bayer
Bayer’s history in China dates back more than a century. Bayer Bayer has business locations in 83 countries around the world. Overall, pharmaceuticals are its second-biggest business after crop science, accounting for 41.6% of sales of about 17 billion...
von Tobias Borgers | Aug 29, 2021 | Bayer
Bayer bolsters its drug discovery capabilities through the acquisition of Vividion, which it says will benefit from an arm’s length business model. The deal – which could be worth up to $2 billion – strengthens Bayer’s small molecule oncology and immunology targets...
von Tobias Borgers | Aug 24, 2021 | Glaxo, Markt
For media and investors only Issued: London UK and Tübingen, Germany / Boston, USA Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s...
